

## HLA-B Protein, Human, Recombinant (E. coli, His)

### General Information

|                       |   |
|-----------------------|---|
| Synonyms:             | B alpha chain;HLA class I histocompatibility antigen, B alpha chain;HLAB;HLA-B;Human leukocyte antigen B (HLA-B)  |
| Protein Construction: | 25-309 aa   |
| Species:              | Human   |
| Expression Host:      | E. coli   |
| Accession:            | P01889  |
| Molecular Weight:     | 38.9 kDa (predicted)  |
| AA Sequence:          | GSMSRYFYTSVSRPGRGEPFISVGVDDTQFVRFSDAASPREEPRAPWIEQEGPEYWRNTQIYKAQAQ<br>TDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQIT<br>QRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITL<br>TWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSQSTVPIV |

### QC Testing

|                      |   |
|----------------------|---|
| Biological Activity: | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.   |
| Purity:              | > 85% as determined by SDS-PAGE.  |
| Endotoxin:           | < 1.0 EU/μg of the protein as determined by the LAL method.   |
| Formulation:         | If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. |

### Preparation and Storage

|                      |  |
|----------------------|--|
| Reconstitution:      | Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 μg/mL. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.  |
| Stability & Storage: | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.<br><small>Actual storage temperature shall be subject to the COA.</small> |
| Shipping:            | In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.   |

### Protein Background

Antigen-presenting major histocompatibility complex class I (MHC I) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9.; Allele B\*07:02: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and mainly a Leu anchor residue at the C-terminus. Presents a long peptide (APRGPHGGAASGL) derived from the cancer-testis antigen CTAG1A/NY-ESO-1, eliciting a polyclonal CD8-positive T cell response against tumor cells. Presents viral epitopes derived from HIV-1 gag-pol (TPQDLNTML) and Nef (RPQVPLRPM). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (SPRWYFYLL). Displays self-peptides including a peptide derived from the signal sequence of HLA-DPB1 (APRTVALTA).; Allele B\*08:01: Presents to CD8-positive T cells viral epitopes derived from EBV/HHV-4 EBNA3 (QAKWRLQTL), eliciting cytotoxic T cell response.; Allele B\*13:02: Presents multiple HIV-1 epitopes derived from gag (RQANFLGKI, GQMREPRGSDI), nef (RQDILDLWI), gag-pol (RQYDQILIE, GQGQWYQI) and rev (LQLPPLERL), all having in common a Gln residue at position 2 and mainly hydrophobic amino acids Leu, Ile or Val at the C-terminus. Associated with successful control of HIV-1 infection.; Allele B\*18:01: Preferentially presents octameric and nonameric peptides sharing a common motif, namely a Glu at position 2 and Phe or Tyr anchor residues at the C-terminus. Presents an EBV/HHV-4 epitope derived from BZLF1 (SELEIKRY). May present to CD8-positive T cells an antigenic peptide derived from MAGEA3 (MEVDPIGHLY), triggering an anti-tumor immune response. May display a broad repertoire of self-peptides with a preference for peptides derived from RNA-binding proteins.; Allele B\*27:05: Presents to CD8-positive T cells immunodominant viral epitopes derived from HCV POLG (ARMILMTHF), HIV-1 gag (KRWIILGLNK), IAV NP (SRYWAIRTR), SARS-CoV-2 N/nucleoprotein (QRNAPRITF), EBV/HHV-4 EBNA4 (HRCQAIRKK) and EBV/HHV-4 EBNA6 (RRIYDLIEL), conferring longterm protection against viral infection. Can present self-peptides derived from cytosolic and nuclear proteins. All peptides carry an Arg at position 2. The peptide-bound form interacts with NK cell inhibitory receptor KIR3DL1 and inhibits NK cell activation in a peptide-specific way, being particularly sensitive to the nature of the amino acid side chain at position 8 of the antigenic peptide. KIR3DL1 fails to recognize HLA-B\*27:05 in complex with B2M and EBV/HHV-4 EBNA6 (RRIYDLIEL) peptide, which can lead to increased activation of NK cells during infection. May present an altered repertoire of peptides in the absence of TAP1-TAP2 and TAPBPL.; Allele B\*40:01: Presents immunodominant viral epitopes derived from EBV/HHV-4 LMP2 (IEDPPFNLS) and SARS-CoV-2 N/nucleoprotein (MEVTPSGTWL), triggering memory CD8-positive T cell response. Displays self-peptides sharing a signature motif, namely a Glu at position 2 and a Leu anchor residue at the C-terminus.; Allele B\*41:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor res

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use**

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481